Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, ...

Novo Nordisk gets CHMP backing for oral GLP-1 agonist Rybelsus in its marketing battle with Eli Lilly, plus positive opinions for Bayer’s diabetes drug Nubeqa, Emergent’s cholera vaccine, and more ...

Mounjaro's label notes, however, that the drug is contraindicated in patients with gastroparesis. Novo Nordisk sent pharmaphorum a statement noting that GLP-1 agonists have been used for years to ...

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...